Introduction {#s1}
============

Carbapenem resistance in *Pseudomonas aeruginosa* has become more common in many countries and is correlated with multidrug resistance (MDR). It is known that carbapenem resistance in *P. aeruginosa* is usually associated with decreased permeability, efflux pump up-regulation and/or the production of metallo-β-lactamases (MBLs).^[@DKP341C1]--[@DKP341C3]^ Different types of MBL have been identified, including IMP, VIM, GIM, SIM and SPM.^[@DKP341C2],[@DKP341C3]^ The VIM-3 MBL was first reported in Taiwan in 2001 and was later found on gene cassettes of the class 1 integron.^[@DKP341C1],[@DKP341C4],[@DKP341C5],[@DKP341C7]^ Recently, we reported a transposon, Tn*6001*, which contains a *bla*~VIM-3~-harbouring integron In450, in a clinical isolate of extensively drug-resistant (XDR) *P. aeruginosa* (XDRPA).^[@DKP341C6]^ However, the overall prevalence of In450 and Tn*6001* in VIM-3-carrying carbapenem-non-susceptible *P. aeruginosa* (CNSPA) is unknown.

Materials and methods {#s2}
=====================

Bacterial isolates {#s2a}
------------------

The 308 non-duplicate CNSPA isolates, defined as isolates resistant to imipenem or meropenem, were collected from 2000 to 2005 at the National Taiwan University Hospital (NTUH), a 2500 bed medical centre in northern Taiwan. If more than one isolate of CNSPA was recovered from the same patient, only the first isolate was included. One of the 308 isolates, NTUH-PA450, was previously reported to carry a transposon Tn*6001*.^[@DKP341C6]^ Colistin-only-susceptible (COS) *P. aeruginosa* was defined as resistance to all antibiotics except colistin (MICs of colistin, ≤2 mg/L) and colistin-only-intermediate (COI) *P. aeruginosa* was defined as resistance to all antibiotics with intermediate resistance to colistin (MIC of colistin, 4 mg/L). The 26 XDRPA isolates were collected in 2003 from six medical centres located in different regions of Taiwan.^[@DKP341C5]^

Antimicrobial susceptibility testing {#s2b}
------------------------------------

MICs of nine antimicrobial agents were determined using an agar dilution method according to CLSI guidelines.^[@DKP341C8]^ The following antimicrobial agents were provided by their manufacturers for use in this study: piperacillin/tazobactam, ceftazidime, cefepime, aztreonam, amikacin, ciprofloxacin, imipenem, meropenem and colistin. XDRPA was defined as *P. aeruginosa* isolates resistant to antimicrobial agents piperacillin/tazobactam, ceftazidime, cefepime, aztreonam, amikacin, ciprofloxacin, imipenem and meropenem, and susceptible or intermediately resistant to colistin.

Detection of MBL genes by PCR amplification and sequencing {#s2c}
----------------------------------------------------------

PCR amplification of MBL genes, including *bla*~IMP-1-9~, *bla*~VIM-1~ and *bla*~VIM-2~ genes, was performed according to previously reported protocols \[[Table S1, available as Supplementary data at *JAC* Online (http://jac.oxfordjournals.org/)](http://jac.oxfordjournals.org/cgi/content/full/dkp341/DC1)\].^[@DKP341C4],[@DKP341C9]^ The types of MBL were confirmed by sequence.

Detection of Tn6001 and bla~VIM-2~-harbouring integron cassette by multiplex PCR {#s2d}
--------------------------------------------------------------------------------

The dissemination of Tn*6001* in clinical isolates was detected by multiplex PCR (the primers are listed in [Table S1](http://jac.oxfordjournals.org/cgi/content/full/dkp341/DC1)) targeting the junctions of the In450 and Tn*6001* backbone structure (GenBank accession number EF138817). The amplicon sizes and locations are shown in Figure [1](#DKP341F1){ref-type="fig"}(a). The *bla*~VIM-2~-harbouring integron cassette was detected by two sets of PCR (Figure [1](#DKP341F1){ref-type="fig"}b) and confirmed by sequencing.

![(a) Genetic organization of transposons Tn*6001*, Tn*6001.1* and Tn*6001.2* in *P. aeruginosa* isolates. Genes are shown as arrows, with their orientation of transcription indicated by the arrowheads. *A4*, *aacA4* gene. The sizes and location of the multiplex PCR amplicons are displayed in Tn*6001*. IRi, left-hand integron inverted repeat (25 bp); IRt, right-hand integron inverted repeat (25 bp); TIRL: left-hand transposon inverted repeat; *f*-TIRR: potential right-hand transposon inverted repeat. (b) Three different *bla*~VIM-2~-harbouring integron cassettes were amplified by two primer sets.](dkp34101){#DKP341F1}

Genotyping by PFGE {#s2e}
------------------

Genotypes of 109 of the 308 CNSPA isolates (30 isolates of XDRPA, including 27 COS *P. aeruginosa* and 3 COI *P. aeruginosa*, and 79 *bla*~VIM-2~ and *bla*~VIM-3~-producing non-XDR CNSPA) from NTUH and 26 XDRPA from six medical centres were determined by PFGE. PFGE analysis was carried out as described previously.^[@DKP341C1]^

Southern blot hybridization {#s2f}
---------------------------

The SpeI-digested chromosome fragments of four clinical isolates were analysed by PFGE. The PFGE gel was then subjected to Southern blotting and hybridized with a DIG (digoxigenin)-labelled *bla*~VIM-3~-specific probe. The hybridization assay was performed as described previously.^[@DKP341C10]^

Results {#s3}
=======

Antimicrobial susceptibility of CNSPA isolates from NTUH {#s3a}
--------------------------------------------------------

A high percentage of cross-resistance to ceftazidime (66%--89%) and cefepime (63%--90%) was found in the CNSPA isolates \[[Table S2, available as Supplementary data at *JAC* Online (http://jac.oxfordjournals.org/)](http://jac.oxfordjournals.org/cgi/content/full/dkp341/DC1)\]. The rate of resistance to monobactam (aztreonam) was also high (52%--90%). It is noted that resistance to ciprofloxacin increased quickly from 2002 to 2004 (76%--93%) while resistance to amikacin ranged from 24% to 56% and there was no resistance to colistin noted in these isolates. Difficulty in treating COS and COI *P. aeruginosa* was found from 2003 to 2005, but the percentages (11%--19% and 0%--3%, respectively) were low. Neither a significant increase in the prevalence of COS or COI *P. aeruginosa* nor shifts of resistance to categories of medically useful antibiotics were noted.

Distribution of MBL genes, integron cassette and Tn6001 {#s3b}
-------------------------------------------------------

*bla*~VIM-2~ and *bla*~VIM-3~ genes were detected in 6 (1.9%) and 88 (28.6%) of the 308 CNSPA from NTUH. The prevalence of the *bla*~VIM-3~ gene ranged from 13% to 32% in non-XDRPA isolates collected during 2000--05 except in 2002. The prevalence of the *bla*~VIM-3~ gene was exceptionally high (52%) in 2002 (Table [1](#DKP341TB1){ref-type="table"}). COS and COI *P. aeruginosa* were first isolated in 2003 and persisted in 2004 and 2005. Furthermore, significant increases in VIM-3 (40% to 67%), In450 (40% to 56%) and Tn*6001* (40% to 50%) from 2003 to 2005 were also noted among COS isolates. Six CNSPA carried a *bla*~VIM-2~-harbouring integron cassette (Figure [1](#DKP341F1){ref-type="fig"}b). Of these integrons, four were identical to AY943084, whereas two (04-14 and 05-43) contained different types of *bla*~VIM-2~-harbouring integron.

###### 

Prevalence of VIM-3, In450 and Tn*6001* in 308 CNSPA isolates at NTUH from 2000 to 2005

                                              No. (%) of isolates                
  ------------------- ----------------------- --------------------- ------------ ------------
  2000 (*n* = 60)     non-XDR^a^ (*n* = 60)   10 (17)               8 (13)       5 (8)
  2001 (*n* = 41)     non-XDR^a^ (*n* = 41)   13 (32)               9 (23)       9 (23)
  2002 (*n* = 21)     non-XDR^a^ (*n* = 21)   11 (52)               5 (24)       3 (14)
  2003 (*n* = 63)     non-XDR^a^ (*n* = 50)   16 (32)               12 (24)^d^   12 (24)^d^
                      XDR                                                        
                      COS^b^ (*n* = 12)       4 (40)                4 (40)       4 (40)
                      COI^c^ (*n* = 1)        1 (100)               0 (0)        0 (0)
  2004 (*n* = 70)     non-XDR^a^ (*n* = 59)   16 (27)               14 (24)      13 (22)
                      XDR                                                        
                      COS^b^ (*n* = 9)        5 (56)                5 (56)       4 (44)
                      COI^c^ (*n* = 2)        2 (100)               1 (50)       1 (50)
  2005 (*n* = 53)     non-XDR^a^ (*n* = 47)   6 (13)                5 (11)^e^    4 (9)^f^
                      XDR                                                        
                      COS^b^ (*n* = 6)        4 (67)                3 (50)       3 (50)
  Total (*n* = 308)                           88 (29)               66 (21)      58 (19)

^a^Non-XDR, non-COS and non-COI.

^b^COS, colistin-only-susceptible, resistant to all antibiotics except colistin.

^c^COI, colistin-only-intermediate, resistant to all antibiotics except intermediate to colistin.

^d^In450.1 (*n* = 1) and Tn*6001.1* (*n* = 1) were found in the same clinical isolate.

^e^In450.1 (*n* = 1) and In450.2 (*n* = 1) were found in two clinical isolates.

^f^Tn*6001.1* (*n* = 1) and Tn*6001.2* (*n* = 1) were found in two clinical isolates.

*bla*~VIM-2~ and *bla*~VIM-3~ genes were detected in 4 (15.4%) and 16 (61.5%) of the 26 XDRPA isolates collected from six medical centres in Taiwan. Twenty-five (96%) were COS and only one (4%) was COI \[[Table S3, available as Supplementary data at *JAC* Online (http://jac.oxfordjournals.org/)](http://jac.oxfordjournals.org/cgi/content/full/dkp341/DC1)\]. Neither In450 nor Tn*6001* was found in the COI isolate. High percentages of In450 and Tn*6001* \[100% (11/11) and 64% (7/11), respectively\] were detected in COS isolates from hospital N1. Similar high percentages (4/10, 40%) were also noted in hospital N2. These findings suggest that the high prevalences of In450 and Tn*6001* are associated with MDR *P. aeruginosa* in Taiwan.

PFGE analysis {#s3c}
-------------

PFGE analysis of the 135 *P. aeruginosa* isolates revealed 60 different pulsotypes. There were 51 different pulsotypes found in 109 CNSPA isolates from NTUH and 16 from 26 XDRPA from six medical centres (seven pulsotypes were distributed among isolates from both NTUH and six medical centres). Four of 15 pulsotypes from the 30 XDRPA isolates and 18 of 49 pulsotypes from 79 non-XDR CNSPA from NTUH and 5 of 16 pulsotypes of the 26 XDRPA from six medical centres had multiple isolates (≥2 isolates).

Structures of two variants of In450 {#s3d}
-----------------------------------

Two variant structures of In450 were found in three non-XDRPA isolates. One integron cassette, designated In450.1, contained the following seven genes: *bla*~VIM-3~, *orf2*, three copies of *aacA4*, *aadB* and a copy of *aacA4*. The other integron cassette, designated In450.2, contained the following five genes: *bla*~VIM-3~, *orf2*, *aacA4*, *aadB* and a copy of *aacA4* (Figure [1](#DKP341F1){ref-type="fig"}a). Both In450.1 and In450.2 were harboured in the Tn*6001* backbone structure, designated Tn*6001.1* and Tn*6001.2*, respectively (Figure [1](#DKP341F1){ref-type="fig"}a).

Mobile DNA Tn6001 {#s3e}
-----------------

Although it was difficult to demonstrate that gene transfer had occurred in the MDR isolate, the results from two closely related clinical isolates from patient A could support the transfer of Tn*6001*. In patient A, an imipenem-susceptible isolate (MIC, 0.12 mg/L) recovered 3 months before the isolation of the carbapenem-resistant isolate (MIC, \>32 mg/L) was used for comparison. PFGE/hybridization analysis revealed only a one band difference between these two isolates \[[Figure S1a, lanes 1 and 2, available as Supplementary data at *JAC* Online (http://jac.oxfordjournals.org/)](http://jac.oxfordjournals.org/cgi/content/full/dkp341/DC1)\]. This DNA fragment contained the *bla*~VIM-3~ gene, which was associated with imipenem resistance ([Figure S1b, lanes 1 and 2](http://jac.oxfordjournals.org/cgi/content/full/dkp341/DC1)). Furthermore, this imipenem-resistant isolate showed the presence of Tn*6001* by multiplex PCR. These findings indicate that the second clinical isolate developed its imipenem resistance phenotype through DNA acquisition and was probably transferred by transposon.

Discussion {#s4}
==========

Consistent with previous studies, the *bla*~VIM-3~ gene was the most common MBL gene in MBL-producing *P. aeruginosa* isolates in Taiwan and was usually harboured by class 1 integrons.^[@DKP341C1],[@DKP341C4],[@DKP341C5]^ The prevalence of *bla*~VIM-3~ in COI or COS *P. aeruginosa* was higher than that in non-XDRPA isolates. Higher prevalences of In450 and Tn*6001* were also detected in COI and COS isolates, both from NTUH and from the six hospitals located in various areas in Taiwan (Tables [1](#DKP341TB1){ref-type="table"} and S3). These findings indicate that In450 and *Tn6001* may account for the transfer of drug resistance genes. However, other mechanisms may also play a role. Since as high as 52% (11/21) of CNSPA contained *bla*~VIM-3~ in 2002, but only a disproportionately low percentage (24%, 5/21) of them carried In450 and 14% (3/21) carried Tn*6001*. These results suggest that unknown mechanisms other than In450 and Tn*6001* may be responsible for the spread of *bla*~VIM-3~.

Tn*6001* was found in different pulsotypes of *P. aeruginosa* isolates. Although it is difficult to demonstrate the gene transfer property of Tn*6001* in the laboratory, results from this study still provide two pieces of evidence supporting the possibility that Tn*6001* is a mobile DNA element and thus disseminated among different isolates. First, the finding that there was only one band difference identified by PFGE and hybridization with a *bla*~VIM-3~-specific probe may suggest that Tn*6001* could be acquired by a susceptible isolate and thus become resistant ([Figure S1](http://jac.oxfordjournals.org/cgi/content/full/dkp341/DC1)). Second, the heterogeneity of pulsotypes for Tn*6001*-containing *P. aeruginosa* isolates revealed polyclonal relatedness, suggesting that horizontal transfer may have occurred. However, several isolates recovered from NTUH (2000--05) and six medical centres (2003) exhibited identical pulsotypes and contained Tn*6001* suggesting the presence of intra-hospital and inter-hospital clonal dissemination.

In addition, Yan *et al.*^[@DKP341C5]^ described that after digestion with EcoRI in MDR *P. aeruginosa* isolates, there were three different DNA fragments (6.2, 6.6 and 8.8 kb) found with a *bla*~VIM-3~-specific probe. These isolates all contained Tn*6001* and one EcoRI site (position 5942 of GenBank accession number EF138817), which was located at *orf2* downstream of *bla*~VIM-3~. This finding suggested that the three different patterns of EcoRI-digested DNA fragments found by Yan *et al.*^[@DKP341C5]^ were due to different locations of Tn*6001* integration. These inferences suggest that the distribution of Tn*6001* might be associated with horizontal transfer.

XDRPA formation may involve antibiotic resistance mechanisms other than Tn*6001* dissemination. A high percentage of aztreonam resistance could be correlated with *bla*~OXA-10~ and *bla*~OXA-17~ spreading,^[@DKP341C5]^ whereas fluoroquinolone resistance has been linked to amino acid changes in topoisomerase types II and IV. We also found that mutations in GyrA (Thr-83→Ile) and ParC (Ser-87→Leu) in the quinolone resistance-determining region may be associated with quinolone resistance (data not shown). Thus, further characterization of XDRPA isolates is a priority and an important issue in Taiwan.

Funding {#s5}
=======

This study was supported by internal funding.

Transparency declarations {#s6}
=========================

None to declare.

Supplementary data {#s7}
==================

[Tables S1, S2 and S3 and Figure S1 are available as Supplementary data at *JAC* Online (http://jac.oxfordjournals.org/)](http://jac.oxfordjournals.org/cgi/content/full/dkp341/DC1).

Supplementary Material
======================

###### \[Supplementary Data\]

We would like to thank the following individuals for providing XDRPA isolates: Jainn-Ming Shyr at Taichung Veterans General Hospital, Taichung, Taiwan; Yin-Ching Chuang and Yi-Chueh Yang at Chi-Mei Medical Center, Tainan, Taiwan; Li-Shin Wang at Buddhist Tzu-Chi General Hospital, Hualien, Taiwan; and Chien-Fang Peng at Kaohsiung Medical University, Kaohsiung, Taiwan.

[^1]: These authors contributed equally to this work.
